RxDoctor Payments Data

Carey Ertz, DO

Family Medicine · Omaha, NENPI 1811901218

Payments from drug & device makers

$1,030in general payments, 2019–2025

Across 65 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$279
  • Novo Nordisk$249
  • Pfizer$119
  • Lilly USA, LLC$61
  • Abbott$57
  • Astellas Pharma US Inc$48
  • plus $218 from 11 others

What the payments were for

  • Food & beverage$1,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,030 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$143,128
Medicare patients
154
Services billed
3,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$38,030
TrulicityDulaglutide31$37,613
JardianceEmpagliflozin18$21,197
Synjardy XrEmpagliflozin/Metformin Hcl15$18,931
Tresiba Flextouch U-100Insulin Degludec14$17,948
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,639
EliquisApixaban19$11,794
Novolog FlexpenInsulin Aspart16$9,244
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$9,232
Breo ElliptaFluticasone/Vilanterol17$7,052
DuleraMometasone/Formoterol11$3,419
Nano 2nd Gen Pen NeedlePen Needle, Diabetic33$2,974
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$2,944
Levothyroxine Sodium328$2,837
Atorvastatin Calcium418$2,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$249$38,03036 claims
Lilly USA, LLCTrulicity$61$37,61331 claims
PfizerEliquis$119$11,79419 claims
MerckDulera$27$3,41911 claims
AbbVieSynthroid$279$1,61829 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$19$49515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →